Lipophilicity of the Cystic Fibrosis Drug, Ivacaftor (VX-770), and Its Destabilizing Effect on the Major CF-causing Mutation: F508del

Stephanie Chin, Maurita Hung, Amy Won, Yu-Sheng Wu, Saumel Ahmadi, Donghe Yang, Salma Elmallah, Krimo Toutah, C. Michael Hamilton, Robert N. Young, Russell D. Viirre, Christopher M. Yip, Christine E. Bear
  • Molecular Pharmacology, June 2018, American Society for Pharmacology & Experimental Therapeutics (ASPET)
  • DOI: 10.1124/mol.118.112177

The authors haven't yet claimed this publication.

Read Publication

In partnership with: